Emerging role of epigenetic therapies in cutaneous T-cell lymphomas

Epigenetics in cancer

(2009) S. Sharma et al.   CARCINOGENESIS

Synergistic interaction of the histone deacetylase inhibitor SAHA with the proteasome inhibitor bortezomib in cutaneous T cell lymphoma

(2009) Ulrike Heider et al.   EUROPEAN JOURNAL OF HAEMATOLOGY

Histone Deacetylase Inhibitor Panobinostat Induces Clinical Responses with Associated Alterations in Gene Expression Profiles in Cutaneous T-Cell Lymphoma

(2008) L. Ellis et al.   CLINICAL CANCER RESEARCH

A phase I clinical trial of the histone deacetylase inhibitor belinostat in patients with advanced hematological neoplasia

(2008) Peter Gimsing et al.   EUROPEAN JOURNAL OF HAEMATOLOGY

Prognostic significance of the therapeutic targets histone deacetylase 1, 2, 6 and acetylated histone H4 in cutaneous T-cell lymphoma

(2008) L Marquard et al.   HISTOPATHOLOGY

Epigenetics in Cancer

(2008) Manel Esteller   NEW ENGLAND JOURNAL OF MEDICINE